ホーム>>Signaling Pathways>> Microbiology & Virology>> HCV>>ACH-806 (GS9132)

ACH-806 (GS9132) (Synonyms: GS9132)

カタログ番号GC32305

ACH-806 (GS9132) は、14 nM の EC50 で C 型肝炎ウイルス (HCV) の複製を阻害できる NS4A アンタゴニストです。

Products are for research use only. Not for human use. We do not sell to patients.

ACH-806 (GS9132) 化学構造

Cas No.: 870142-71-5

サイズ 価格 在庫数 個数
1mg
$690.00
在庫あり
5mg
$1,105.00
在庫あり
10mg
$1,767.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

ACH-806 is an NS4A antagonist which can inhibit Hepatitis C Virus (HCV) replication with an EC50 of 14 nM.

ACH-806 is an NS4A antagonist which can inhibit Hepatitis C Virus (HCV) replication with an EC50 of 14 nM. ACH-806 treatment results in significant reductions of both NS3 and NS4A in the transfected cells. This finding is reminiscent of ACH-806-treated replicon cells in which the amounts of NS3 and NS4A are also both decreased. The total amount of NS3 in the ACH-806-treated sample is reduced by ~6-fold (100/16) and causes a reduction of NS4A-bound NS3 ~29-fold (261/9). The levels of labeled NS3 and NS4A immunoprecipitated by anti-NS3 antibody are apparently reduced after the treatment of ACH-806. ACH-806 also induces significant decreases of NS3 and NS4A and promotes p14 formation in the parental replicon cells but not in the ACH-806-resistant replicon cells[1].

[1]. Yang W, et al. ACH-806, an NS4A antagonist, inhibits hepatitis C virus replication by altering the composition of viral replication complexes. Antimicrob Agents Chemother. 2013 Jul;57(7):3168-77.

レビュー

Review for ACH-806 (GS9132)

Average Rating: 5 ★★★★★ (Based on Reviews and 34 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for ACH-806 (GS9132)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.